Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6277MR)

This product GTTS-WQ6277MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13048MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14916MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ10566MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ589MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ15390MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ9216MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ12560MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ6491MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW